-
Mashup Score: 2Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age - 1 month(s) ago
A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Source: www.ajmc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Melanoma Warning Signs and Images - 1 month(s) ago
Learn melanoma warning signs, symptoms and signs of skin cancer. See images of moles to help find melanoma early when it is easier to cure.
Source: www.skincancer.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 13Age-related changes in skin may contribute to melanoma metastases - 2 month(s) ago
Age-related changes that cause the skin to stiffen and become less elastic may also contribute to higher rates of metastatic skin cancer in older people, according to research by investigators from the …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 41
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Pembrolizumab adjuvant therapy was shown to significantly improve recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB or IIC melanoma in earlier analyses of the randomized, double-blind, phase III KEYNOTE-716 study (ClinicalTrials.gov identifier: NCT03553836). We report results of the protocol-specified final analysis of DMFS for KEYNOTE-716. Overall, 976 patients were randomly allocated to pembrolizumab (n = 487) or placebo (n = 489). As of January 4, 2023, median follow-up was 39.4 months (range, 26.0-51.4 mont
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
3 year update for KN716 now online @JCO_ASCO. Foundational data for adjuvant #melanoma emphasizing patients with stage IIB/C dz are at high risk & anti-PD1 is highly effective to prevent recurrence. Next step - biomarker work to optimize patient selection! https://t.co/cI55QkTwmE https://t.co/XmWMWAHr1i
-
-
Mashup Score: 27Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Groundbreaking TIL Therapy OK’d for Melanoma - 2 month(s) ago
Abstract: After decades of research, the first tumor-infiltrating lymphocyte therapy was greenlighted by the FDA to treat patients with inoperable or metastatic melanoma—Iovance’s lifileucel (Amtagvi). The agency’s approval is not only the first for a cellular immunotherapy but also for a solid tumor.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1
Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1A prediction model for response to immune checkpoint inhibition in advanced melanoma - 2 month(s) ago
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
Older men have an increased risk for second primary invasive melanoma (SPIM) following an initial primary melanoma diagnosis and could benefit from more surveillance in the years following their first diagnosis, according to a study #Melanoma https://t.co/Tt4FmmfFas via @AJMC